Proteins > Glutamate receptor ionotropic, NMDA 2B
Page last updated: 2024-08-07 17:04:54
Glutamate receptor ionotropic, NMDA 2B
A glutamate receptor ionotropic, NMDA 2B that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q13224]
Synonyms
GluN2B;
Glutamate [NMDA] receptor subunit epsilon-2;
N-methyl D-aspartate receptor subtype 2B;
NMDAR2B;
NR2B;
N-methyl-D-aspartate receptor subunit 3;
NR3;
hNR3
Research
Bioassay Publications (58)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (12.07) | 18.2507 |
2000's | 17 (29.31) | 29.6817 |
2010's | 26 (44.83) | 24.3611 |
2020's | 8 (13.79) | 2.80 |
Compounds (55)
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
6,7-dichloroquinoxaline-2,3-dione | Homo sapiens (human) | IC50 | 42,941.7533 | 2 | 3 |
tacrine | Homo sapiens (human) | IC50 | 44.0000 | 2 | 2 |
amantadine | Homo sapiens (human) | Ki | 10.5000 | 1 | 1 |
arcaine | Homo sapiens (human) | IC50 | 44.5550 | 2 | 2 |
chlorpromazine | Homo sapiens (human) | IC50 | 0.8500 | 2 | 2 |
racemethorphan | Homo sapiens (human) | IC50 | 0.3650 | 2 | 2 |
ifenprodil | Homo sapiens (human) | IC50 | 0.1519 | 9 | 9 |
ifenprodil | Homo sapiens (human) | Ki | 0.0100 | 10 | 10 |
ketamine | Homo sapiens (human) | IC50 | 4.1059 | 2 | 2 |
ketamine | Homo sapiens (human) | Ki | 0.6700 | 4 | 4 |
kynurenic acid | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
memantine | Homo sapiens (human) | IC50 | 5.3100 | 4 | 4 |
memantine | Homo sapiens (human) | Ki | 0.6933 | 3 | 3 |
orphenadrine | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
procyclidine | Homo sapiens (human) | Ki | 1.7000 | 1 | 1 |
phencyclidine | Homo sapiens (human) | IC50 | 1.2589 | 1 | 1 |
phencyclidine | Homo sapiens (human) | Ki | 0.0324 | 3 | 3 |
2,3-dihydroxyquinoxaline | Homo sapiens (human) | IC50 | 51,169.4000 | 2 | 2 |
glutamic acid | Homo sapiens (human) | IC50 | 0.0700 | 2 | 2 |
eliprodil | Homo sapiens (human) | Ki | 0.0130 | 9 | 9 |
budipine | Homo sapiens (human) | Ki | 11.7000 | 1 | 1 |
6,7-dichloroquinoxaline-2,3-dione | Homo sapiens (human) | IC50 | 281,171.4000 | 2 | 2 |
ly 293558 | Homo sapiens (human) | IC50 | 12.1000 | 1 | 1 |
besonprodil | Homo sapiens (human) | IC50 | 0.0060 | 4 | 4 |
besonprodil | Homo sapiens (human) | Ki | 0.0300 | 1 | 1 |
dizocilpine | Homo sapiens (human) | IC50 | 0.0090 | 1 | 1 |
dizocilpine | Homo sapiens (human) | Ki | 0.0040 | 1 | 2 |
cns 5161 | Homo sapiens (human) | Ki | 0.0019 | 1 | 1 |
cp 101,606 | Homo sapiens (human) | IC50 | 0.0370 | 3 | 3 |
cp 101,606 | Homo sapiens (human) | Ki | 0.0110 | 2 | 2 |
6-methyl-2-(phenylethynyl)pyridine | Homo sapiens (human) | IC50 | 18.0000 | 1 | 1 |
7-chloro-thiokynurenate | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
4-(5-(4-bromophenyl)-3-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4,5-dihydro-1h-pyrazol-1-yl)-4-oxobutanoic acid | Homo sapiens (human) | IC50 | 113.0000 | 1 | 1 |
tcn 201 | Homo sapiens (human) | IC50 | 15.1365 | 4 | 4 |
l 745870 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
levorphanol | Homo sapiens (human) | IC50 | 2.6000 | 2 | 2 |
dextromethorphan | Homo sapiens (human) | Ki | 1.6800 | 1 | 1 |
dextrorphan | Homo sapiens (human) | IC50 | 0.2460 | 1 | 1 |
dextrorphan | Homo sapiens (human) | Ki | 0.2200 | 1 | 1 |
licostinel | Homo sapiens (human) | IC50 | 2,944.2230 | 2 | 2 |
ro 25-6981 | Homo sapiens (human) | IC50 | 0.0240 | 6 | 6 |
ro 25-6981 | Homo sapiens (human) | Ki | 0.0486 | 4 | 4 |
eaa-090 | Homo sapiens (human) | IC50 | 3.8150 | 2 | 2 |
pd 174494 | Homo sapiens (human) | IC50 | 0.0045 | 2 | 2 |
fpl 15896ar | Homo sapiens (human) | Ki | 0.5600 | 1 | 1 |
3-((2-methyl-1,3-thiazol-4-yl)ethynyl)piperidine | Homo sapiens (human) | IC50 | 300.0000 | 1 | 1 |
(4-benzylpiperidin-1-yl)-(6-hydroxy-1h-indol-2-yl)methanone | Homo sapiens (human) | IC50 | 0.0160 | 2 | 2 |
tqx 173 | Homo sapiens (human) | IC50 | 46.0000 | 1 | 1 |
(1rs,1's)-peaqx | Homo sapiens (human) | IC50 | 14.8040 | 2 | 2 |
methoxydine | Homo sapiens (human) | IC50 | 15.8489 | 1 | 1 |
nitd 609 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
wms 1410 | Homo sapiens (human) | IC50 | 0.0185 | 1 | 1 |
wms 1410 | Homo sapiens (human) | Ki | 0.0490 | 4 | 4 |
Drugs with Activation Measurements
Drugs with Other Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
felbamate | Homo sapiens (human) | Kapp | 6,444.5000 | 20 | 20 |
licostinel | Homo sapiens (human) | Kb | 0.0050 | 1 | 1 |
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.Journal of medicinal chemistry, , Aug-27, Volume: 58, Issue:16, 2015
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.Journal of medicinal chemistry, , May-13, Volume: 53, Issue:9, 2010
[no title available]Journal of medicinal chemistry, , 09-22, Volume: 65, Issue:18, 2022
[no title available]European journal of medicinal chemistry, , Mar-15, Volume: 190, 2020
Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands.ACS medicinal chemistry letters, , May-14, Volume: 11, Issue:5, 2020
Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.Bioorganic & medicinal chemistry, , 01-15, Volume: 28, Issue:2, 2020
Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.Journal of medicinal chemistry, , 01-10, Volume: 62, Issue:1, 2019
Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold.MedChemComm, , Feb-01, Volume: 10, Issue:2, 2019
[no title available]European journal of medicinal chemistry, , Jan-20, Volume: 144, 2018
Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold.European journal of medicinal chemistry, , Sep-05, Volume: 157, 2018
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?MedChemComm, , May-01, Volume: 8, Issue:5, 2017
Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.Bioorganic & medicinal chemistry, , Dec-01, Volume: 22, Issue:23, 2014
Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors.Bioorganic & medicinal chemistry, , Feb-01, Volume: 22, Issue:3, 2014
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.Journal of medicinal chemistry, , Apr-25, Volume: 56, Issue:8, 2013
Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[18F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 20, Issue:18, 2010
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors.Bioorganic & medicinal chemistry letters, , May-01, Volume: 18, Issue:9, 2008
Repurposing of Drugs-The Ketamine Story.Journal of medicinal chemistry, , 11-25, Volume: 63, Issue:22, 2020
Ketamine esters and amides as short-acting anaesthetics: Structure-activity relationships for the side-chain.Bioorganic & medicinal chemistry, , 04-01, Volume: 27, Issue:7, 2019
Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 21, Issue:7, 2011
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.Journal of medicinal chemistry, , May-13, Volume: 53, Issue:9, 2010
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.European journal of medicinal chemistry, , May-15, Volume: 194, 2020
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.European journal of medicinal chemistry, , Oct-15, Volume: 180, 2019
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.Journal of medicinal chemistry, , Aug-27, Volume: 58, Issue:16, 2015
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.Journal of medicinal chemistry, , May-13, Volume: 53, Issue:9, 2010
Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.Journal of medicinal chemistry, , Aug-14, Volume: 51, Issue:15, 2008
Design, synthesis, and biological evaluation of tricyclic heterocycle-tetraamine conjugates as potent NMDA channel blockers.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 17, Issue:17, 2007
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.European journal of medicinal chemistry, , May-15, Volume: 194, 2020
Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 21, Issue:7, 2011
Methylated analogues of methyl (R)-4-(3,4-dichlorophenylacetyl)- 3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (GR-89,696) as highly potent kappa-receptor agonists: stereoselective synthesis, opioid-receptor affinity, receptor selectivity, and functioJournal of medicinal chemistry, , Aug-16, Volume: 44, Issue:17, 2001
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
[no title available]European journal of medicinal chemistry, , Mar-15, Volume: 190, 2020
Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.Bioorganic & medicinal chemistry, , 01-15, Volume: 28, Issue:2, 2020
Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists.Bioorganic & medicinal chemistry, , 08-15, Volume: 27, Issue:16, 2019
[no title available]European journal of medicinal chemistry, , Jan-20, Volume: 144, 2018
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?MedChemComm, , May-01, Volume: 8, Issue:5, 2017
Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.European journal of medicinal chemistry, , Jun-30, Volume: 116, 2016
Benzo[7]annulene-based GluN2B selective NMDA receptor antagonists: Surprising effect of a nitro group in 2-position.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 25, Issue:24, 2015
Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.Bioorganic & medicinal chemistry, , Dec-01, Volume: 22, Issue:23, 2014
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
(3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist.Journal of medicinal chemistry, , Jul-09, Volume: 36, Issue:14, 1993
Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.European journal of medicinal chemistry, , Jun-30, Volume: 116, 2016
Oxamides as novel NR2B selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Aug-02, Volume: 14, Issue:15, 2004
Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Nov-03, Volume: 13, Issue:21, 2003
Theoretical studies on the structure and symmetry of the transmembrane region of glutamatergic GluR5 receptor.Journal of medicinal chemistry, , Jul-10, Volume: 51, Issue:13, 2008
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 21, Issue:11, 2011
Oxamides as novel NR2B selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Aug-02, Volume: 14, Issue:15, 2004
2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Mar-10, Volume: 13, Issue:5, 2003
Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Feb-24, Volume: 13, Issue:4, 2003
Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.Journal of medicinal chemistry, , 01-10, Volume: 62, Issue:1, 2019
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.Journal of medicinal chemistry, , Apr-25, Volume: 56, Issue:8, 2013
Theoretical studies on the structure and symmetry of the transmembrane region of glutamatergic GluR5 receptor.Journal of medicinal chemistry, , Jul-10, Volume: 51, Issue:13, 2008
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
CoMFA and homology-based models of the glycine binding site of N-methyl-d-aspartate receptor.Journal of medicinal chemistry, , Apr-24, Volume: 46, Issue:9, 2003
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.Journal of medicinal chemistry, , Nov-25, Volume: 37, Issue:24, 1994
Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.Journal of medicinal chemistry, , 01-10, Volume: 62, Issue:1, 2019
Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold.MedChemComm, , Feb-01, Volume: 10, Issue:2, 2019
[no title available]European journal of medicinal chemistry, , Jan-20, Volume: 144, 2018
Oxamides as novel NR2B selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Aug-02, Volume: 14, Issue:15, 2004
2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Mar-10, Volume: 13, Issue:5, 2003
Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Nov-03, Volume: 13, Issue:21, 2003
Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Feb-24, Volume: 13, Issue:4, 2003
Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist.Bioorganic & medicinal chemistry letters, , Aug-20, Volume: 11, Issue:16, 2001
[no title available]European journal of medicinal chemistry, , Mar-15, Volume: 190, 2020
Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.Bioorganic & medicinal chemistry, , 10-15, Volume: 25, Issue:20, 2017
Role of the phenolic OH moiety of GluN2B-selective NMDA antagonists with 3-benzazepine scaffold.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 26, Issue:3, 2016
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010
Enables
This protein enables 9 target(s):
Target | Category | Definition |
amyloid-beta binding | molecular function | Binding to an amyloid-beta peptide/protein. [GOC:hjd] |
NMDA glutamate receptor activity | molecular function | An cation channel that opens in response to binding by extracellular glutmate, but only if glycine is also bound and the membrane is depolarized. Voltage gating is indirect, due to ejection of bound magnesium from the pore at permissive voltages. [GOC:mah, PMID:10049997] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
zinc ion binding | molecular function | Binding to a zinc ion (Zn). [GOC:ai] |
glycine binding | molecular function | Binding to glycine, aminoethanoic acid. [GOC:ai] |
glutamate binding | molecular function | Binding to glutamate, the anion of 2-aminopentanedioic acid. [GOC:ai] |
glutamate-gated calcium ion channel activity | molecular function | Enables the transmembrane transfer of a calcium ion by a channel that opens when glutamate has been bound by the channel complex or one of its constituent parts. [GOC:mtg_transport, ISBN:0815340729] |
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential | molecular function | Any ligand-gated ion channel activity, occurring in the presynaptic membrane, that is involved in regulation of presynaptic membrane potential. [GOC:dos, PMID:15145529, PMID:19558451] |
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential | molecular function | Any transmitter-gated ion channel activity that is involved in regulation of postsynaptic membrane potential. [GO_REF:0000061, GOC:TermGenie, PMID:20200227] |
Located In
This protein is located in 11 target(s):
Target | Category | Definition |
cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
lysosome | cellular component | A small lytic vacuole that has cell cycle-independent morphology found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions. [GOC:mah, ISBN:0198506732] |
late endosome | cellular component | A prelysosomal endocytic organelle differentiated from early endosomes by lower lumenal pH and different protein composition. Late endosomes are more spherical than early endosomes and are mostly juxtanuclear, being concentrated near the microtubule organizing center. [NIF_Subcellular:nlx_subcell_20090702, PMID:11964142, PMID:2557062] |
endoplasmic reticulum membrane | cellular component | The lipid bilayer surrounding the endoplasmic reticulum. [GOC:mah] |
cytoskeleton | cellular component | A cellular structure that forms the internal framework of eukaryotic and prokaryotic cells. The cytoskeleton includes intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles. [GOC:mah, PMID:16959967, PMID:27419875] |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
cell surface | cellular component | The external part of the cell wall and/or plasma membrane. [GOC:jl, GOC:mtg_sensu, GOC:sm] |
postsynaptic density | cellular component | An electron dense network of proteins within and adjacent to the postsynaptic membrane of an asymmetric, neuron-neuron synapse. Its major components include neurotransmitter receptors and the proteins that spatially and functionally organize them such as anchoring and scaffolding molecules, signaling enzymes and cytoskeletal components. [GOC:BHF, GOC:dos, GOC:ef, GOC:jid, GOC:pr, GOC:sjp, http://molneuro.kaist.ac.kr/psd, PMID:14532281, Wikipedia:Postsynaptic_density] |
neuron projection | cellular component | A prolongation or process extending from a nerve cell, e.g. an axon or dendrite. [GOC:jl, http://www.cogsci.princeton.edu/~wn/] |
postsynaptic membrane | cellular component | A specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft). Neurotransmitters cross the synaptic cleft and transmit the signal to the postsynaptic membrane. [ISBN:0198506732] |
synaptic membrane | cellular component | A specialized area of membrane on either the presynaptic or the postsynaptic side of a synapse, the junction between a nerve fiber of one neuron and another neuron or muscle fiber or glial cell. [GOC:BHF, PMID:20410104] |
Active In
This protein is active in 2 target(s):
Target | Category | Definition |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
postsynaptic density membrane | cellular component | The membrane component of the postsynaptic density. This is the region of the postsynaptic membrane in which the population of neurotransmitter receptors involved in synaptic transmission are concentrated. [GOC:dos] |
Part Of
This protein is part of 1 target(s):
Target | Category | Definition |
NMDA selective glutamate receptor complex | cellular component | An assembly of four or five subunits which form a structure with an extracellular N-terminus and a large loop that together form the ligand binding domain. The C-terminus is intracellular. The ionotropic glutamate receptor complex itself acts as a ligand gated ion channel; on binding glutamate, charged ions pass through a channel in the center of the receptor complex. NMDA receptors are composed of assemblies of NR1 subunits (Figure 3) and NR2 subunits, which can be one of four separate gene products (NR2A-D). Expression of both subunits are required to form functional channels. The glutamate binding domain is formed at the junction of NR1 and NR2 subunits. NMDA receptors are permeable to calcium ions as well as being permeable to other ions. Thus NMDA receptor activation leads to a calcium influx into the post-synaptic cells, a signal thought to be crucial for the induction of NMDA-receptor dependent LTP and LTD. [http://www.bris.ac.uk/Depts/Synaptic/info/glutamate.html] |
Involved In
This protein is involved in 22 target(s):
Target | Category | Definition |
glutamate receptor signaling pathway | biological process | The series of molecular signals initiated by the binding of glutamate to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:mah, GOC:signaling, PMID:9131252] |
chemical synaptic transmission | biological process | The vesicular release of classical neurotransmitter molecules from a presynapse, across a chemical synapse, the subsequent activation of neurotransmitter receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse. [GOC:jl, MeSH:D009435] |
brain development | biological process | The process whose specific outcome is the progression of the brain over time, from its formation to the mature structure. Brain development begins with patterning events in the neural tube and ends with the mature structure that is the center of thought and emotion. The brain is responsible for the coordination and control of bodily activities and the interpretation of information from the senses (sight, hearing, smell, etc.). [GOC:dph, GOC:jid, GOC:tb, UBERON:0000955] |
learning or memory | biological process | The acquisition and processing of information and/or the storage and retrieval of this information over time. [GOC:jid, PMID:8938125] |
calcium-mediated signaling | biological process | Any intracellular signal transduction in which the signal is passed on within the cell via calcium ions. [GOC:signaling] |
ionotropic glutamate receptor signaling pathway | biological process | The series of molecular signals initiated by glutamate binding to a glutamate receptor on the surface of the target cell, followed by the movement of ions through a channel in the receptor complex, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:signaling, ISBN:0198506732] |
response to ethanol | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethanol stimulus. [GOC:go_curators] |
regulation of synaptic plasticity | biological process | A process that modulates synaptic plasticity, the ability of synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers. [GOC:dph, GOC:jid, GOC:tb, PMID:11891290] |
regulation of neuronal synaptic plasticity | biological process | A process that modulates neuronal synaptic plasticity, the ability of neuronal synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers. [GOC:jid, PMID:11891290] |
protein heterotetramerization | biological process | The formation of a protein heterotetramer, a macromolecular structure consisting of four noncovalently associated subunits, of which not all are identical. [GOC:go_curators] |
positive regulation of synaptic transmission, glutamatergic | biological process | Any process that activates, maintains or increases the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate. [GOC:ai] |
calcium ion transmembrane import into cytosol | biological process | A process in which a calcium ion is transported from one side of a membrane to the other into the cytosol by means of some agent such as a transporter or pore. [GOC:vw] |
monoatomic cation transmembrane transport | biological process | The process in which a monoatomic cation is transported across a membrane. Monatomic cations (also called simple cations) are positively charged ions consisting of exactly one atom. [GOC:dos, GOC:vw] |
excitatory chemical synaptic transmission | biological process | Synaptic transmission that results in an excitatory postsynaptic potential. [GOC:dos] |
regulation of presynaptic membrane potential | biological process | Any process that modulates the potential difference across a presynaptic membrane. [GOC:dph, GOC:ef] |
negative regulation of dendritic spine maintenance | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of dendritic spine maintenance. [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:24328732] |
regulation of monoatomic cation transmembrane transport | biological process | Any process that modulates the frequency, rate or extent of cation transmembrane transport. [GO_REF:0000058, GOC:TermGenie, PMID:15304482] |
positive regulation of excitatory postsynaptic potential | biological process | Any process that enhances the establishment or increases the extent of the excitatory postsynaptic potential (EPSP) which is a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential. [GOC:bf, GOC:BHF] |
positive regulation of cysteine-type endopeptidase activity | biological process | Any process that activates or increases the frequency, rate or extent of cysteine-type endopeptidase activity. [GOC:obol] |
long-term synaptic potentiation | biological process | A process that modulates synaptic plasticity such that synapses are changed resulting in the increase in the rate, or frequency of synaptic transmission at the synapse. [GOC:dgh, GOC:dph] |
synaptic transmission, glutamatergic | biological process | The vesicular release of glutamate from a presynapse, across a chemical synapse, the subsequent activation of glutamate receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse. [GOC:dos] |
excitatory postsynaptic potential | biological process | A process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential. [GOC:dph, GOC:ef] |